[ad_1]
Millions of Americans those with diseases or medical treatments who have weakened their immune systems and are already fully vaccinated against Covf with Pfizer or Moderna vaccines will be allowed to take a third dose, according to federal decisions made on Thursday night and Friday.
The decisions of the Food and Drug Administration and Immunization Practice Advisory Committee, an external advisory team from the Centers for Disease Control and Prevention, U.S. health policy show that research shows transplant recipients and cancer patients. they are not fully protected by making two shots — and also to patients who were receiving unacceptable doses on their own. It effectively changes the range of vaccines allowed for people with weak immune systems from two to three doses, giving the third dose 28 days or more after the second.
But it’s not a blanket change. It only includes people who are called “moderate or severe immune risk” by the FDA and ACIP. The third shot is only allowed for those over the age of 12, as no vaccine has been allowed for minors or children. And it does not support extra shots for people with immune problems among the 12 million recipients of the Johnson & Johnson single-dose vaccine, as there is still no data to predict their reactions.
The FDA and the commission were careful not to call third-dose “boosters,” if they hoped to improve the initial protection of people with low immunity and renew the immunity of the rest of the population if the vaccine’s effectiveness waned against future variants. But overall, it may be debatable. The World Health Organization has called on rich countries to stop giving extra doses until poor countries get more shots.
The decision to increase the dose to people at risk of immunity comes from a long time ago. ACIP, which is a team of medical researchers and representatives of social professionals who support the CDC shape vaccination policy, examined evidence of relocation last month. CDC Director Rochelle Walensky immediately announced her arrival during a appearance on the White House Covid-19 response team on Thursday evening. “This action is to ensure that our most vulnerable (who may need an additional dose to improve their biological response to vaccines) are better protected against Covid-19,” he said.
FDA has changed orientation on vaccines on Thursday night, changing permits for emergency use of the Pfizer and Moderna formulas to include a three-dose series and to set the stage for the committee, which held a discussion on Friday morning. That meeting ended unanimously with a vote in favor of the third dose.
But the immediate driver of the change — along with the rise of the contagious Delta variant in the U.S. — was research. Canada and France were published in the year on Wednesday and Thursday New England Journal of Medicine (although previously shared with federal agencies). Both documented that small groups of transplants who received two doses of the vaccine had low antibody levels, but achieved high immune protection after the third dose.
“I really think these results are definitive; I think it’s a slam dunk, ”said Atul Humar, director of physics and transplantation at the University of Toronto and lead author of the Canadian test before playing at the FDA and CDC on Thursday. in the recipients of the third dose, compared to the participants who received the placebo. “I think the results are credible enough that this will lead to a change in regulatory guidelines by recommending a third dose to these patients,” he said.
[ad_2]
Source link
